Alexander Rittenberg1, Anika L Hines2, Anika A H Alvanzo3, Geetanjali Chander4. 1. Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD, 21287, United States. Electronic address: alexander.rittenberg@vcuhealth.org. 2. Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD, 21287, United States. Electronic address: anika.hines@vcuhealth.org. 3. Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD, 21287, United States. Electronic address: aalvanzo.ucg@gmail.com. 4. Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD, 21287, United States. Electronic address: gchande1@jhmi.edu.
Abstract
BACKGROUND: Alcohol use disorder is a highly prevalent disease with multiple medications available for treatment. The overall prevalence of patients receiving pharmacotherapy is believed to be low and the characteristics and comorbidities that affect receipt are not well-established. METHODS: We created a dataset from Truven Health Analytics MarketScan Commercial Claims and Encounters Database of patients with an outpatient encounter for alcohol abuse or dependence in 2014. We subsequently identified patient characteristics, comorbid medical, psychiatric, or substance use disorders, as well as encounter provider specialties and, using multivariable logistic regression, assessed which variables correlated with increased or decreased receipt of pharmacotherapy for alcohol use disorder for this population. RESULTS: In our dataset of 123,355 patients, patient receipt of pharmacotherapy for alcohol use disorder was 3.3 %, and 9.3 % when restricted to the former diagnosis of alcohol dependence only. Male sex, younger age, alcohol-related liver disease, and cannabis use disorders correlated with decreased receipt whereas comorbid major depressive disorders and anxiety disorders correlated with increased receipt. Compared to patients seen by psychiatrists, those seen by primary medical doctors had a lower odds of receiving pharmacotherapy. CONCLUSIONS: Pharmacotherapy for alcohol use disorder is an underutilized treatment modality with a low prevalence of prescription in insured individuals. Patients with specific characteristics and comorbidities are less likely to receive this treatment and greater focus on these patients and in the primary care setting can allow for increased prescribing of these medications.
BACKGROUND:Alcohol use disorder is a highly prevalent disease with multiple medications available for treatment. The overall prevalence of patients receiving pharmacotherapy is believed to be low and the characteristics and comorbidities that affect receipt are not well-established. METHODS: We created a dataset from Truven Health Analytics MarketScan Commercial Claims and Encounters Database of patients with an outpatient encounter for alcohol abuse or dependence in 2014. We subsequently identified patient characteristics, comorbid medical, psychiatric, or substance use disorders, as well as encounter provider specialties and, using multivariable logistic regression, assessed which variables correlated with increased or decreased receipt of pharmacotherapy for alcohol use disorder for this population. RESULTS: In our dataset of 123,355 patients, patient receipt of pharmacotherapy for alcohol use disorder was 3.3 %, and 9.3 % when restricted to the former diagnosis of alcohol dependence only. Male sex, younger age, alcohol-related liver disease, and cannabis use disorders correlated with decreased receipt whereas comorbid major depressive disorders and anxiety disorders correlated with increased receipt. Compared to patients seen by psychiatrists, those seen by primary medical doctors had a lower odds of receiving pharmacotherapy. CONCLUSIONS: Pharmacotherapy for alcohol use disorder is an underutilized treatment modality with a low prevalence of prescription in insured individuals. Patients with specific characteristics and comorbidities are less likely to receive this treatment and greater focus on these patients and in the primary care setting can allow for increased prescribing of these medications.
Authors: Benjamin J Oldfield; Kathleen A McGinnis; E Jennifer Edelman; Emily C Williams; Adam J Gordon; Kathleen Akgün; Stephen Crystal; Lynn E Fiellin; Julie R Gaither; Joseph L Goulet; P Todd Korthuis; Brandon D L Marshall; Amy C Justice; Kendall Bryant; David A Fiellin; Kevin L Kraemer Journal: J Subst Abuse Treat Date: 2019-11-06
Authors: Alex H S Harris; Elizabeth Oliva; Thomas Bowe; Keith N Humphreys; Daniel R Kivlahan; Jodie A Trafton Journal: Psychiatr Serv Date: 2012-07 Impact factor: 3.084
Authors: Tami L Mark; Cheryl A Kassed; Rita Vandivort-Warren; Katharine R Levit; Henry R Kranzler Journal: Drug Alcohol Depend Date: 2008-09-25 Impact factor: 4.492
Authors: Delphine Praud; Matteo Rota; Jürgen Rehm; Kevin Shield; Witold Zatoński; Mia Hashibe; Carlo La Vecchia; Paolo Boffetta Journal: Int J Cancer Date: 2015-10-28 Impact factor: 7.396
Authors: Augustin G L Vannier; Jessica E S Shay; Vladislav Fomin; Suraj J Patel; Esperance Schaefer; Russell P Goodman; Jay Luther Journal: JAMA Netw Open Date: 2022-05-02